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Introduction

▼
Diabetic kidney disease (DKD) is one of the severe diabetic complications and about 20 % diabetic patients undergone renal failure with death consequence because of the end stage of kidney disease [1] . Metabolic abnormality has been considered as the main pathological factor promoting the development of DKD. Among them, hyperglycemia is a major causal factor and it can induce oxidative stress by either reactive oxygen species (ROS) over production or damaging anti-oxidative capacity including nuclear factor erythroid-derived 2-like 2 (Nrf2) system [2, 3] . Furthermore, oxidative stress is causally linked to the activation of inflammatory signaling [4] . Oxidative stress together with the redox-sensitive inflammatory process can further damage renal tissue and its function [4] . Therefore, preventing hyperglycemia-mediated oxidative stress and blocking inflammatory activation are potential effective strategies for treating DKD and developing effective therapeutic drugs. With the rapid increase in the population of Type II diabetes mellitus (T2DM), research on effective treatment against diabetic complications including DKD is an important and urgent task. However, current therapy for DKD is mainly relied on metabolic control and available drugs targeted to DKD in clinical practice are not sufficient to block its development. In addition, during past decades a few drugs have been developed for curing this disease [1] . Since hyperglycemia-induced oxidative stress is the major pathological mechanism involved in diabetic complications, targeting Nrf2 anti-oxidative system and searching effective synthetic drugs have attracted intensive interest for DKD therapy. Our group has recently reported that the anti-oxidative capacity of Nrf2 system is impaired in high fat diet-fed mice [5] , revealing a
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▼
Curcumin has a therapeutic potential in treating diabetic kidney disease (DKD) while potential mechanisms underlining this beneficial effect remain to be elucidated. In the present study, curcumin intervention was performed in patients with Type II diabetes mellitus (T2DM) by oral intake of curcumin at the dose of 500 mg/ day for a period of 15-30 days. Nephritic excretion of urinary micro-albumin (U-mAlb) and blood metabolic indexes were assessed before and after this intervention. In addition, the lipid oxidation index, malondialdehyde (MDA) in plasma and the status of anti-oxidative Nrf2 system in blood lymphocytes were measured. The effect of curcumin on inflammation was assessed by measuring plasma lipopolysaccharide (LPS) content and inflammatory signaling protein in blood lymphocytes. A self-comparison method was used for assessing statistical significances of these measurements. Here we show that curcumin intervention markedly attenuated U-mAlb excretion without affecting metabolic control of participated patients. In addition, curcumin reduced plasma MDA level with enhanced the Nrf2 system specifically regulated protein, NAD(P)H quinone oxidoreductase 1 (NQO-1) together with other anti-oxidative enzymes in patients' blood lymphocytes. Furthermore, we observed reduced plasma LPS content and increased IκB, an inhibitory protein on inflammatory signaling in patient's lymphocytes after curcumin administration. Finally, several gut bacterials important for maintaining gut barrier integrity and function were upregulated by curcumin.
In conclusion, short-term curcumin intervention ablates DKD progress with activating Nrf2 antioxidative system and anti-inflammatory efficacies in patients with T2DM.
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defective function of the major anti-oxidative system in insulinresistant condition. In addition, several studies have identified the defectiveness of Nrf2 system in diabetic condition [6, 7] . More importantly, other groups have observed that the activation of Nrf2 function attenuated DKD progression in both renal function and morphology with reductions in oxidative stress and pro-inflammatory mediators [8, 9] . These findings suggest that deficient Nrf2 function is involved in pathological process of oxidative stress while oxidative stress, consequent inflammation and damages can be combated by the anti-oxidative master, Nrf2 system. However, the newly developed drug, bardoxolone methyl targeted on activating Nrf2 system appeared exciting in its effectiveness in treating DKD but has failed to pass clinical trial due to its severe toxicity [4] . In this aspect, natural compounds with low toxicity and the potent efficacy on Nrf2 activation can be a promising strategy for developing new candidate for DKD treatment. Among these, curcumin has been demonstrated to be a strong Nrf2 activator in animal studies [10] and more importantly, it has been shown to be effective in preventing and retarding various diabetic complications, including DKD [11] [12] [13] . Curcumin, a principal curcuminoid found in turmeric belonging to natural polyphenol compound is considered as a compound with high safety since it is rich in the spicy curry and widely consumed [11] [12] [13] . In addition, animal studies have shown that curcumin prevents β-cell death and attenuates insulin resistance [14, 15] . Therefore, with the therapeutic potential in metabolic control and the relative safety in treating diabetic complications curcumin can be a promising drug for further study in depth. Proteinuria is an important feature of overt DKD reflecting functional aberrance of renal function and glomerular damage. In the preclinical stage of DKD a small increase of urinary microalbumin (U-mAlb) excretion has been positively associated with consequent initiation of overt DKD and has been used as a biomarker for predicting DKD development [16] . Therefore, the assessment of U-mAlb content in diabetic patients has became an important test for both predicting and monitoring renal complications of diabetic patients. Furthermore, it has been used as a good indicator for evaluating therapeutic efficacy of drugs as well [16] . In the present study, we applied U-mAlb measurement to assess whether curcumin can be beneficial for blocking DKD development by oral intake of curcumin for a short period of 15-30 days. To explore potential working mechanisms of curcumin, we assessed plasma lipopolysaccharide (LPS) content and its correlation with the effect of curcumin on U-mAlb. Furthermore, blood lymphocytes of the patients were extracted and alterations in redox regulating and inflammatory signaling were examined. Due to the reversal capacity of curcumin on repressed Nrf2 function demonstrated in a vivo animal study [10] , we further explored the effects of curcumin in humans to exam whether curcumin intervention could exert an activating effect on Nrf2 system.
Materials and Methods
▼
Ethics statement
This study was approved by the Ethic Committee of the Fujian University of Traditional Chinese Medicine with all human subjects provided written, informed consent.
Curcumin intervention of patients
All participated subjects with T2DM and DKD were diagnosed according to the standards of American Diabetes Association (ADA) recommendations [17] . 4 out of 14 diabetic patients were diagnosed overt DKD while other 3 were in preclinical stage of DKD with elevated U-mAlb and the rest of diabetic patients were within normal range in U-mAlb excretion. Curcumin was purchased from ORGANIKA Health Products (Richmond, Canada) and was orally administrated to patients in a dose of 500 mg per day for 15 days and the patients with overt DKD were administrated to an extended time for 30 days. During the period of curcumin medication, the patients with pharmacological drug intakes were kept on their routine as shown in • ▶ Table 1 . Table 1 Characteristics and drug treatment of the patients. 
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U-mAlb assay
Overnight urine samples (8PM to 8AM) were collected in a same container, mixed and U-mAlb assay was performed by enzyme linked immunosorbent assay (ELISA ) method with Quik Read U-mAlb kit (Orion Diagnostica Oy, Espoo, Finland) following the manufacturer's instructions.
Metabolic assessments
Overnight fasting blood samples were collected. Fasting blood glucose (FBG), insulin (INS), C-peptide (C-P), total triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), alanine transaminase (ALT), aspartate transaminase (AST), serum creatinine (Scr) and urea nitrogen (BUN) were analyzed in clinical laboratories before and after the 15-day curcumin intervention.
LPS assay
Ambient levels of plasma LPS were quantified by LPS ELISA kit (CUSABIO, Wuhan, China) following the manufacturer's instructions.
Fecal bacteria PCR analysis
Fresh fecal specimens were collected from participants over a 24 h period and stored in − 20 °C immediately until they were processed. DNA was extracted from 1 g fecal material using a reported method [18] . 2 specific primers were designed from the variable regions of the 16SrRNA gene sequence of the 3 bacteria listed in • ▶ Table 2 with all primers purchased from Sangon Biotech (Shanghai, China). Standard PCR analysis was carried out in 50 μl reaction volume containing 2.5 U Taq polymerase (Takara, Dalian, China), 100 ng DNA template with denature temperature at 94 °C, using the annealing temperatures shown in • ▶ Table 2 for 60 s and extended at 72 °C for 34 cycles. The PCR products were separated with 1.2 % agarose gel containing ethidium bromide and the DNA bands with the expected sizes were visualized under UV light.
MDA assay
Plasma MDA was measured by MDA assay kit (Jiancheng Company, Nanjing, China) following the manufacturer's instructions.
Lymphocyte isolation and western blot analysis
Lymphocytes were isolated by density centrifugation from the blood samples of patients using lymphocyte isolation kit (Shanghai Kehua Bio-Engineering., Shanghai, China). Lymphocytes were lysed in the buffer containing 20 mM Tris (pH 7.5), 137 mM NaCl, 2 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 2 mM EDTA, 1 % Tx-100, 10 % glycerol, 2 μg/ml aprotinin, 5 μg/ml leupeptin and 2 mM PMSF. Sample protein concentration was measured by BCA protein assay kit (Beyotime Institute of Biotechnology, Jiangsu, China). Proteins were dissolved in sodium dodecyl sulfate (SDS) sample loading buffer and heated at 95 °C for 5 min. Equal amounts of proteins (20 μg) were separated by 10 % denaturing SDS-polyacrylamide gel. Proteins were transferred on nitrocellulose membranes. Following the transfer, the membranes were blocked in 5 % non-fat milk powder dissolved in buffer containing 25 mM Tris, pH 7.5, 154 mM NaCl and 0.1 % Tween-20 for 1 h at room temperature. The membranes were then probed with primary antibodies overnight at 4 °C. The membranes were washed and incubated with secondary antibody conjugated to horseradish peroxidase (Santa Cruz, CA). Immunoreactive proteins were visualized with enhanced chemiluminescence (Beijing ComWin Biotech., Beijing, China). The intensities of the bands were quantified by phosphorimager analysis. The primary antibodies against Nrf2 and β-actin were purchased from Santa Cruz Biotechnology (Shanghai, China). Antibodies against IκBα and superoxide dismutase (SOD) 1 were purchased from Proteintech Group (Guangzhou, China). SOD2 antibody was obtained from Abgent (San Diego, CA, USA). NAD(P)H:quinone oxidoreductase-1 (NQO-1) antibody was from Cell Signaling Technology (Guangzhou, China). Caspase 3 antibody was from Sangon Biotech (Shanghai, China).
Statistics
All data were expressed as mean ± SEM. Statistical significance was assessed by paired-sample T test or analysis of variance and p-value < 0.05 was considered to be statistically significant.
Results
▼
Curcumin intervention dramatically reduces U-mAlb excretion without affecting metabolic control
To reduce excessive excretion of urinary albumin is a major clinical task and its improvement serves as a judgment index for an effective treatment of DKD. To evaluate the therapeutic potential of curcumin on DKD, we started to assess its efficacy on U-mAlb content. The method we used for measuring U-mAlb defines > 20 mg/L as abnormal range. Before curcumin treatment, 4 patients had clinically manifested DKD (U-mAlb > 200 mg/L) and 3 had preclinical stage of DKD (U-mAlb: 20-200 mg/L) whereas the remaining 7 had normal albuminuria. The average content of U-mAlb prior to curcumin medication in these 14 patients was 214.9 ± 104.5 mg/L ( • ▶ Fig. 1a ).
While after 15-day curcumin treatment, the amount of U-mAlb was dramatically reduced to 69.7 ± 41.9 mg/L (~ 70 % reduction, n = 14, p < 0.05). Further analysis showed a more significant reduction in patients with DKD than patients with normal U-mAlb content (69. Fig. 1c, d) . We calculated creatinine clearance rate, an indicator of kidney function and found that the curcumin therapy did not significantly alter renal function ( • ▶ Fig. 1e ). The hepatic functions of those patients were not significantly altered ( • ▶ Table 3 ).
To examine whether the alteration of metabolic control could explain the beneficial effect of curcumin on DKD, we measured metabolic indexes of these patients before and after curcumin intervention. As shown in • ▶ Table 4 , neither FBG nor blood lipids including TG and TC were altered, while only LDL-L content was decreased following curcumin therapy ( • ▶ Table 4 ).
Curcumin intervention reduces plasma MDA level and activates Nrf2 system in blood lymphocytes
To examine whether curcumin could affect redox balance in diabetic patients, we measured MDA, an index of lipid peroxidation and observed that after curcumin treatment plasma MDA level in the patients was dramatically reduced (~75 % reduction, 13 .93 nM ± 1.18 vs. 3.54 ± 0.64 nM, n = 7, p < 0.001, • ▶ Fig. 2a ). It appears that curcumin reduced MDA level to a greater magnitude in patients with DKD than those without DKD but it did not reach a statistical significance (DKD: 80.2 ± 15.3 % reduction vs. without DKD: 62.3 ± 10.4 % reduction, p = 0.37). To further explore potential mechanisms underlining the anti-oxidative effect of curcumin, we assessed the functional status of Nrf2 system in blood lymphocytes. Our results of western blot showed 
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All patients with T2DM were received curcumin intervention for 15 days. Overnight fasting blood samples were taken at the beginning and the end of curcumin treatment with following analysis on glucose and lipid levels as described in the "Materials and Methods". NS, no significance; * * , p < 0.01; BMI, body mass index; FBG, fasting blood glucose; INS, insulin; C-P, C-peptide; TC, total cholesterol; TG, total triglyceride; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein . 2c ). Further analysis of curcumin effect on upregulating NQO-1 in patients' subgroups showed its effectiveness in both patients with and without DKD (without DKD: 2.37 ± 0.21 vs. DKD: 1.46 ± 0.92 fold increase after curcumin treatment), but no statistical significant difference was found between the 2 groups. There was a seemly greater effect of curcumin in increasing SOD contents in patients with DKD but again there were no statistical significant differences compared to patients without DKD (SOD1: 1.01 ± 0.31 without DKD vs. 2.38 ± 0.54 fold increase in DKD; SOD2: 1.36 ± 0.06 without DKD vs. 1.79 ± 0.21 fold increase in DKD).
Curcumin intervention reduces plasma LPS level and modulates gut microbiota
To evaluate inflammatory status of these patients, we first assessed their plasma LPS levels. As shown in • ▶ Fig. 3a , plasma LPS content, an inducer of inflammation was decreased after curcumin intervention in these patients (~25 % reduction, 38.11 ± 4.34 ng/ml vs. 28.78 ± 4.97 ng/ml, n = 7, p < 0.01). To assess any difference of curcumin effect on lowering LPS levels in subgroups of these patients, we compared LPS levels in patients with DKD to those without DKD. It appeared that curcumin reduced LPS level to a great degree in patients with DKD but this was not statistically significant (without DKD: 10.5 ± 7.8 % reduction vs. DKD: 38.7 ± 16.8 % reduction, p = 0.20). Furthermore, in order to detect the pathological relation of LPS with DKD, a regression analysis was performed on plasma LPS level with U-mAlb content based on their reduced percentages after curcumin intervention. We observed that in patients with DKD there was a significant negative correlation between LPS level with U-mAlb content (R gut bacterial is a major resource of blood LPS, we further explored whether gut microbiota can be modulated by curcumin. As shown in • ▶ Fig. 3c , multiple bacterials important for maintaining normal balance of gut microbiota and gut barrier function were increased after curcumin intake ( • ▶ Fig. 3c ).
Curcumin intervention represses inflammatory and apoptotic signaling proteins in blood lymphocytes
We then detected the effect of curcumin on inflammatory signaling protein in blood lymphocytes. We observed that the inflammation inhibitory protein IκB was clearly increased after curcumin treatment (optical density: 0.62 ± 0.03 vs. 1.24 ± 0.10, n = 6, p < 0.01, • ▶ Fig. 4a ). Oxidative stress can directly lead to cellular damage together with inflammation-initiated apoptotic process, which is a common mechanism of renal damage in DKD. We detected the expression level of apoptotic caspase 3 by western blotting and observed that the content of this protein was reduced following 15-day curcumin therapy (optical den- sity: 0.99 ± 0.12 vs. 0.42 ± 0.02, n = 6, p < 0.01, • ▶ Fig. 4b ). Further analysis of curcumin effects on upregulating IκB and repressing caspase 3 showed a similar effect in both patients with and without DKD (data now shown).
Discussion and Conclusions
▼
The beneficial effect of curcumin on attenuating DKD has been found more than a decade [19] . Since then, most studies have been conducted in animal models and revealed several mechanistic aspects of curcumin in retarding DKD progress [12] . The therapeutic effect of curcumin on DKD has been attributed to the general improvement of metabolic control including its lowering efficacies on hyperglycemia and hyperlipidemia [20, 21] . In addition, the direct renal efficacies of curcumin on anti-oxidative stress and anti-inflammation contribute to its therapeutic effect on DKD [22] . However, only a few studies have tested its therapeutic potential in humans with emphasizing on its working mechanisms. In the present study we confirmed that curcumin supplementation to patients with T2DM can play a significant role in attenuating U-mAlb excretion and in addition, we revealed its efficacies in activating Nrf2 anti-oxidative system, repressing LPS level and inflammatory signaling. Diabetic hyperglycemia exerts significant pathological roles in the triggering and aggravating DKD. In addition, hyperlipidemia commonly existed in diabetic patients may further aggravate DKD [23] . Although curcumin has been reported to lower blood glucose in diabetic patient [20] , we could not find significant alterations by curcumin supplementation on glucose or lipid levels in these patients. These can be due to a much lower dose (500 mg/day) we used in this study than another reported one (5 g/day) [20] . In spite of lacking effect on metabolic control, curcumin was still able to significantly attenuate U-mAlb content in our patients. These observations are interesting since it is suggested that the beneficial efficacies of curcumin on DKD is not necessary to rely on its modulation on metabolic control. Rather than, other mechanisms such as, curcumin-evoked redox balance and LPS lowering effect can be more important for its therapeutic effect on DKD. Indeed, in the present study we further provided the evidence that curcumin plays systemically an antioxidative stress and anti-inflammatory effects by showing the lowering effect of curcumin on plasma MDA and LPS levels in the participated diabetic patients. In support, following curcumin supplementation Nrf2 system function in blood lymphocytes was activated together with inflammatory signaling inhibition. These data provide a potential molecular signaling basis for therapeutic effect of curcumin on DKD. Diabetes is associated with a low grade inflammation while gut bacterial-derived LPS can be a contributing factor to cause a systemic inflammation in addition to adipose tissue-derived cytokines. More specifically, the etiological role of LPS in DKD progression was indicated by a study showing a positive correlation of LPS with DKD development [24] . Since curcumin can modulate both gut microbiota [25] and plasma LPS level, we assumed that the part of anti-inflammatory effect of curcumin is exerted via the modulation of local gut microbiota. Gut Gramnegative bacteria is a major resource of plasma LPS via local intestinal absorption into the blood stream. In contrast, several Gram-positive species have been reported to reduce LPS absorption either by maintaining intact gut barrier or keeping bacteria flora in balance [26] [27] [28] [29] [30] . Our PCR experiments assessing gut bacterial species revealed a clear modification effect of curcumin on microbiota. Because bacteroides, bifidobacterium and lactobacillus are the bacterial capable to reduce plasma LPS level either by limiting Gram-negative bacteria over-growth in the gut or to reduce LPS absorption by maintaining normal gut mucosa barrier, our observation of curcumin-upregulated these bacteria raises a novel possibility that curcumin can modulate gut microbiota to suppress LPS level and its evoked renal inflammatory damage in diabetic patients. Mechanically, LPS can bind to-toll-like receptor (TLR) 4 in the kidney evoking inflammatory response and harmful effect to renal podocytes and therefore, DKD [31, 32] . In addition, TLR is upregulated in DKD patients [24, 31] . Indeed, in our experiments, we observed repressive effects of curcumin on inflammatory signaling and caspase 3 apoptotic proteins in blood lymphocytes. These findings point to a novel mechanism of curcumin in the treatment of DKD through attenuating gut-derived LPS absorption into the blood and consequent blocking LPS-induced renal inflammation and damage. In summary, our study suggests 2 working mechanisms of curcumin exerting its beneficial effect which may be important to delay DKD progress. First, curcumin can prevent DKD, exampled by reducing U-mAlb excretion, probably by directly exerting anti-oxidative effect via Nrf2 activation. Second, curcumin attenuates DKD by modulating gut microbiota/LPS/inflammation pathway. 
